Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group IND.197 -- Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor (HER2) Negative, Recurrent/Metastatic Breast Cancer - was centrally activated 25 May 2010.

http://www.ctg.queensu.ca/trials/ind/i197/197.html